These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 26468228)

  • 1. Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy.
    Dhodapkar MV; Sexton R; Das R; Dhodapkar KM; Zhang L; Sundaram R; Soni S; Crowley JJ; Orlowski RZ; Barlogie B
    Blood; 2015 Nov; 126(22):2475-8. PubMed ID: 26468228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SOX2 immunity and tissue resident memory in children and young adults with glioma.
    Vasquez JC; Huttner A; Zhang L; Marks A; Chan A; Baehring JM; Kahle KT; Dhodapkar KM
    J Neurooncol; 2017 Aug; 134(1):41-53. PubMed ID: 28620836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
    Tai YT; Cho SF; Anderson KC
    Front Immunol; 2018; 9():1822. PubMed ID: 30147691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.
    Jørgensen NG; Klausen U; Grauslund JH; Helleberg C; Aagaard TG; Do TH; Ahmad SM; Olsen LR; Klausen TW; Breinholt MF; Hansen M; Martinenaite E; Met Ö; Svane IM; Knudsen LM; Andersen MH
    Front Immunol; 2020; 11():595035. PubMed ID: 33240282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.
    Spisek R; Kukreja A; Chen LC; Matthews P; Mazumder A; Vesole D; Jagannath S; Zebroski HA; Simpson AJ; Ritter G; Durie B; Crowley J; Shaughnessy JD; Scanlan MJ; Gure AO; Barlogie B; Dhodapkar MV
    J Exp Med; 2007 Apr; 204(4):831-40. PubMed ID: 17389240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
    Garfall AL; Stadtmauer EA; Hwang WT; Lacey SF; Melenhorst JJ; Krevvata M; Carroll MP; Matsui WH; Wang Q; Dhodapkar MV; Dhodapkar K; Das R; Vogl DT; Weiss BM; Cohen AD; Mangan PA; Ayers EC; Nunez-Cruz S; Kulikovskaya I; Davis MM; Lamontagne A; Dengel K; Kerr ND; Young RM; Siegel DL; Levine BL; Milone MC; Maus MV; June CH
    JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.
    Kearl TJ; Jing W; Gershan JA; Johnson BD
    J Immunol; 2013 Jun; 190(11):5620-8. PubMed ID: 23616570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
    Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow-derived mesenchymal stem cells inhibit CD8
    Liu Z; Mi F; Han M; Tian M; Deng L; Meng N; Luo J; Fu R
    Clin Exp Immunol; 2021 Jul; 205(1):53-62. PubMed ID: 33735518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
    Burrack AL; Spartz EJ; Raynor JF; Wang I; Olson M; Stromnes IM
    Cell Rep; 2019 Aug; 28(8):2140-2155.e6. PubMed ID: 31433988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
    Furness AJ; Quezada SA; Peggs KS
    Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
    [No Abstract]   [Full Text] [Related]  

  • 12. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.
    Bailur JK; McCachren SS; Doxie DB; Shrestha M; Pendleton K; Nooka AK; Neparidze N; Parker TL; Bar N; Kaufman JL; Hofmeister CC; Boise LH; Lonial S; Kemp ML; Dhodapkar KM; Dhodapkar MV
    JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31013254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-immunizing with PD-L1 induces CD8
    Guo S; Xiao P; Li B; Wang W; Wang S; Lv T; Xu X; Chen C; Huang L; Li Z; Tang L; Peng L; Wang H
    Int Immunopharmacol; 2020 Jul; 84():106516. PubMed ID: 32334387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
    Costa F; Vescovini R; Marchica V; Storti P; Notarfranchi L; Dalla Palma B; Toscani D; Burroughs-Garcia J; Catarozzo MT; Sammarelli G; Giuliani N
    Front Immunol; 2020; 11():613007. PubMed ID: 33488620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
    Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
    J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
    Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
    Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation.
    Kobold S; Tams S; Luetkens T; Cao Y; Sezer O; Bartels BM; Reinhard H; Templin J; Bartels K; Hildebrandt Y; Lajmi N; Marx A; Haag F; Bokemeyer C; Kröger N; Atanackovic D
    Clin Dev Immunol; 2011; 2011():302145. PubMed ID: 22190969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
    Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
    Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease.
    Tiemann M; Samoilova V; Atiakshin D; Buchwalow I
    BMC Res Notes; 2020 Mar; 13(1):139. PubMed ID: 32143684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients.
    Lendvai N; Gnjatic S; Ritter E; Mangone M; Austin W; Reyner K; Jayabalan D; Niesvizky R; Jagannath S; Bhardwaj N; Chen-Kiang S; Old LJ; Cho HJ
    Cancer Immun; 2010 Jan; 10():4. PubMed ID: 20108890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.